<DOC>
	<DOCNO>NCT02375256</DOCNO>
	<brief_summary>Healthy adult receive BCG Study Day -84 , follow randomization Study Day 0 receive 2 booster dos blind fashion either AERAS-402 ( N=9 ) placebo ( N=2 ) Study Days 0 28 . Subjects follow total 98 day .</brief_summary>
	<brief_title>A Leukapheresis Study Immune Responses Healthy US Adults Who Receive BCG Vaccination Followed Boosting With AERAS-402</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled study . At least 13 , 16 , subject meet eligibility criterion receive prime vaccination BCG ( 1-8 x 105 colony form unit [ CFU ] intradermally [ ID ] ) Study Day -84 . Thirteen BCG-vaccinated subject complete protocol-specified procedure continue meet eligibility criterion enrol randomized Study Day 0 10:3 ratio receive study vaccine ( either AERAS-402 3 x 1010 virus particle [ vp ] intramuscularly [ IM ] placebo IM ) Study Days 0 28 , base time completion screen . Eleven subject randomize ( N=9 AERAS-402 ; N=2 placebo ) analyze . Enrollment stop 11 plan 13 subject randomize , felt number subject sufficient address objective study .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Is male female 2 . Provided write informed consent prior study related procedure 3 . Is age ≥18 year ≤45 year Study Day 84 . 4 . Has Body Mass Index ( BMI ) ≥19 &lt; 33 nomogram ( see appendix ) 5 . Has general good health , confirm medical history physical examination 6 . Females physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must avoid pregnancy acceptable method avoid pregnancy 28 day prior Study Day 84 end study . 7 . Females physically capable pregnancy must negative serum pregnancy test within 7 day prior Study Day 84 AND negative urine pregnancy test Study Day 84 , Study Day 0 , Study Day 28 . 8 . Has commit avoid elective surgery duration study 9 . Has ability complete study visit require per protocol able contact telephone 1 . Acute illness , oral temperature ≥37.5°C , axillary lymphadenopathy Study Day 84 , Study Day 0 , Study Day 28 . 2 . Any following laboratory result blood urine collect within 7 day prior Study Day 84 ( evaluate per local laboratory parameter ) : Abnormal hemoglobin hematocrit Abnormal white blood cell count , absolute neutrophil count , absolute lymphocyte count Elevated creatinine , total bilirubin , AST , ALT , alkaline phosphatase ( ALP ) 3 . Evidence chronic hepatitis ( e.g. , hepatitis B core antibody , hepatitis C antibody , ) 4 . Laboratory test ( e.g. , QuantiFERON®TB ) evidence Mycobacterium tuberculosis ( Mtb ) infection 5 . History residence tuberculosisendemic country , per WHO 2008 `` highburden '' definition 6 . History treatment active latent tuberculosis infection 7 . History evidence ( include chest Xray ) active tuberculosis 8 . Shared residence within last year individual antituberculosis treatment culture smear positive tuberculosis 9 . History allergic disease reaction likely exacerbate component BCG study vaccine 10 . History autoimmune disease immunosuppression 11 . Current household contact occupational exposure individual know significant immunosuppression 12 . History evidence physical examination systemic disease , acute chronic illness , opinion investigator , may interfere evaluation safety immunogenicity vaccine , include axillary lymphadenopathy 13 . History laboratory evidence past , present future possible immunodeficiency state include ( limited ) laboratory indication HIV infection 14 . History alcohol drug abuse within past 2 year 15 . History cheloid formation 16 . Previous medical history may compromise safety subject study 17 . Any current medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely subject comply protocol 18 . Inability discontinue daily medication study period except follow : Contraceptives Multivitamins Inhaled topical corticosteroid 19 . Tobacco smoke pack cigarette day , cannabis smoking three day per week 20 . Received immunosuppressive medication within 45 day prior Study Day 84 ( inhaled topical corticosteroid permit ) 21 . Received investigational drug vaccine product within 182 day prior Study Day 84 plan participation investigational study study period 22 . Received investigational Mtb vaccine time prior Study Day 84 23 . Received vaccination immunotherapy BCG product time prior Study Day 84 . 24 . Received immunoglobulin blood product within 45 day prior Study Day 84 . 25 . Received standard vaccine within 45 day prior Study Day 84 except inactivate influenza vaccine may receive within 2 week prior Study Day 84 . 26 . History high risk sexual behavior since 1977 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>